Clinical trials: Exudative Age Related Macular Degeneration
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Time Efficiency Comparison of Two IntraVitreal Injection Techniques
Prospective, single-center, randomized, clinical trial (RCT) comparing the time efficiency and safety of a single-use intravitreal injection (IVI) guide versus a traditional technique using a dual blade speculum among patients…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion With Macular Edema, Uveitic Macular Edema
- Trial name
- TIVI (NCT04455399)
- Testing
- Intravitreal injection guide (Malosa), Dual Blade Eyelid Speculum
- Where
- Philippines
- Volunteers
- 200 people
- Sponsor
- Peregrine Eye and Laser Institute
Low Vision, Neovascular Age-related Macular Degeneration
Timing of Low Vision Rehabilitation in Anti- Vascular Endothelial Growth Factor (VEGF) Therapy
The purpose of this research is to collect preliminary data in preparation for conducting a randomized clinical trial to determine the relative effectiveness of vision rehabilitation in improving overall visual ability (primary…
- Trial name
- TRAVIT (NCT03065907)
- Testing
- Vision rehabilitation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University
AMD, nAMD
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD).
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
- Trial name
- ATMOSPHERE (NCT04704921)
- Testing
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Where
- 89 sites in United States
- Volunteers
- 671 people
- Sponsor
- AbbVie
Age-Related Macular Degeneration (AMD), Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
The Efficacy of Home OCT Supported Management in Patients Diagnosed With Neovascular-AMD and Undergoing a Drug Switch to Faricimab
Age-related macular degeneration (AMD) is a common eye disease that can lead to vision loss. The neovascular ("wet") form of AMD is usually treated with repeated injections into the eye.
- Trial name
- NCT07744984
- Testing
- Home Optical Coherence Tomography (Home OCT)
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Rabin Medical Center
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study Assessing AR-13503 Implant in Subjects With nAMD or DME
First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)
- Trial name
- NCT03835884
- Testing
- AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Aerie Pharmaceuticals
Macular Degeneration
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
This study will test the safety and effectiveness of combining a laser treatment called photodynamic therapy, or PDT, with injections into the eye of the steroid triamcinolone acetonide for treating age-related macular…
- Trial name
- NCT00100009
- Testing
- TAC-PF, Triamcinolone Acetonide
- Where
- 23 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Eye Institute (NEI)
Macular Degeneration
A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD
The purpose of this study is to determine the way and rate that the study medication, JSM6427 a potent, highly specific integrin α5β1-antagonist is absorbed, broken-down and eliminated from the body when it is given as a single…
- Trial name
- NCT00536016
- Testing
- JSM6427
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Jerini Ophthalmic
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Researchers are looking for a better way to treat participants who have diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD). DME is a diabetes-related eye disorder.
- Trial name
- DEUTERON (NCT06591598)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 51 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
This study is a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.
- Trial name
- BLUE SKY (NCT04543331)
- Testing
- brolucizumab
- Where
- 41 sites in Germany
- Volunteers
- 572 people
- Sponsor
- Novartis Pharmaceuticals
Exudative Age-related Macular Degeneration
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD).
- Trial name
- Nexus (NCT01414153)
- Testing
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
- Where
- 44 sites in United States
- Volunteers
- 158 people
- Sponsor
- Lpath, Inc.
Neovascular Age-related Macular Degeneration
Safety and Efficacy of AM712 in Patients with NAMD
The purpose of this Phase 1 study is comprised of multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AM712 in patients with…
- Trial name
- NCT05345769
- Testing
- AM712(ASKG712)
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- AffaMed Therapeutics Limited
Exudative Age-Related Macular Degeneration
Home Monitoring in eAMD Treatment
The goal of this observational clinical study is to collect more information about the efficacy of Aflibercept 8 mg injections in people with eAMD.
- Trial name
- HOME (NCT07340372)
- Testing
- Aflibercept 8mg
- Where
- 8 sites in Portugal
- Volunteers
- 80 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Age-related Macular Degeneration
A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of E10030 intravitreous injection when administered as monotherapy or in combination with Lucentis® 0.5 mg/eye in subjects with…
- Trial name
- NCT00569140
- Testing
- E10030
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Ophthotech Corporation
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
MMP-9 Inhibition for Recalcitrant Wet AMD
Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world.
- Trial name
- NCT04504123
- Testing
- Doxycycline Hyclate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Iowa
AMD, Exudative Macular Degeneration
CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)
The main objective of this study is to analyze a new noninvasive imaging examination, OCT angiography, in the evaluation of neovascular remodeling and early signs of recurrence of wet AMD undergoing treatment on OCTA and to…
- Trial name
- COCTAEyl (NCT03803631)
- Where
- 5 sites in France
- Volunteers
- 49 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Macular Degeneration
Treatment -Resistant Neovascular Age-Related Macular Degeneration
The purpose of this study is to determine if treatment of Age Related Macular Degeneration (AMD) with a new medication,rituximab is effective.
- Trial name
- Rituximab (NCT02332941)
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Presence of Retinal Fluid, Changes in Macular Pigment Optical Density
Aflibercept 8 mg for nAMD: Early Anatomical and Functional Changes
Neovascular age-related macular degeneration (nAMD) is one of the main causes of irreversible vision loss in older people worldwide.
- Trial name
- NCT07074054
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Federico II University
Neovascular Age-Related Macular Degeneration
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor [VA]-masked), active-comparator study designed to assess the efficacy, safety, and pharmacokinetics (PK) of 100mg/ml delivered via the Port…
- Trial name
- Archway (NCT03677934)
- Testing
- PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal Injections of 10 mg/mL Ranibizumab
- Where
- 77 sites in United States
- Volunteers
- 415 people
- Sponsor
- Hoffmann-La Roche
Exudative Age-Related Macular Degeneration
Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration
Age-related macular degeneration is a leading cause of visual impairment in older adults. In its exudative form, repeated intravitreal injections of anti-VEGF agents are required to control disease activity.
- Trial name
- AFLIWEST (NCT07423429)
- Testing
- aflibercept 8 mg
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Nantes University Hospital
To Evaluate the Safety and Tolerability of Intravitreal Injection of LX109 in Patients With nAMD
An Exploratory Clinical Trial Evaluating LX109 Gene Therapy in Patients With nAMD
To evaluate the safety and tolerability of intravitreal injection of LX109 in patients with nAMD.
- Trial name
- NCT06022744
- Testing
- LX109
- Volunteers
- 12 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine